Filter Results:
(1,253)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
- 06 Jun 2017
- First Look
First Look at New Research and Ideas: June 6, 2017
regulatory pathway, the biosimilars pathway, on the strategy of a major pharmaceutical firm that finds its largest product (60% of revenue) at risk. The case reviews the rationale for the pathway, the emerging biosimilars market entrants,... View Details
Keywords: Sean Silverthorne
- 12 May 2009
- First Look
First Look: May 12, 2009
Case 809-026 An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access... View Details
Keywords: Martha Lagace
- 09 Jan 2007
- First Look
First Look: January 9, 2007
http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=707413 Teva Pharmaceutical Industries, Ltd. Harvard Business School Case 707-441 Purchase this case: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=707441 ... View Details
Keywords: Martha Lagace
- July 2017 (Revised July 2019)
- Supplement
"Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (B)
By: Nori Gerardo Lietz and Ricardo Andrade
The B Case of "Dr. My Eyes" provides the answer as to what happened after the ending fact pattern in Case A and the imminent choices faced by the protagonist in the primary case. At the end of the Case A, Bess Weatherman of Warburg Pincus, must chose one option of two... View Details
Keywords: Private Equity; Health Care and Treatment; Mergers and Acquisitions; Corporate Governance; Decision Choices and Conditions; Outcome or Result; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Lietz, Nori Gerardo, and Ricardo Andrade. "Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (B). Harvard Business School Supplement 218-029, July 2017. (Revised July 2019.)
- July 2016 (Revised July 2019)
- Teaching Plan
Doctor My Eyes: The Acquisition of Bausch & Lomb by Warburg Pincus (A)
By: Nori Gerardo Lietz and Ricardo Andrade
In early 2010, senior partners at Warburg Pincus met to review a report on Bausch & Lomb Incorporated, the firm's largest investment at the time. Warburg Pincus had led a group of investors in acquiring Bauch & Lomb on October 26, 2007, taking the company private and... View Details
- April 2016 (Revised July 2019)
- Case
"Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (A)
In early 2010, senior partners at Warburg Pincus met to review a report on Bausch & Lomb Incorporated, the firm's largest investment at the time. Warburg Pincus had led a group of investors in acquiring Bauch & Lomb on October 26, 2007, taking the company private and... View Details
Keywords: Health Care; Mergers ＆ Acquisitions; Governance; Buyout; Private Equity; Finance; Mergers and Acquisitions; Corporate Governance; Health Care and Treatment; Reports; Business Model; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States
Lietz, Nori Gerardo. "Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (A). Harvard Business School Case 216-021, April 2016. (Revised July 2019.)
- August 2003
- Teaching Note
Pharmacyclics: Financing Research and Development (TN)
By: Malcolm P. Baker and Richard S. Ruback
Teaching Note for (9-201-056). View Details
- 2001
- Other Unpublished Work
Clusters of Innovation Initiative: San Diego
The study contains a conceptual framework for assessing the competitiveness of regional economies, an analysis of the San Diego region overall, as well as detailed assessments of two representative clusters—biotechnology/pharmaceuticals and communications. The report... View Details
Keywords: Clusters; Economics; Industry Clusters; Economy; Growth and Development; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; San Diego
Porter, Michael E. "Clusters of Innovation Initiative: San Diego." Council on Competitiveness, Washington, DC, May 2001. (Report.)
- 2014
- Working Paper
Bio-Piracy or Prospering Together? Fuzzy Set and Qualitative Analysis of Herbal Patenting by Firms
By: Prithwiraj Choudhury and Tarun Khanna
Since the 1990s, several Western firms have filed patents based on medicinal herbs from emerging markets, evoking protests from local stakeholders against 'bio-piracy'. We explore conditions under which firms and local stakeholders share rents from such patents. Our... View Details
Keywords: Rents From New Technology; Local Stakeholders; Herbal Patents; QCA; Fuzzy Set Analysis; Qualitative Case Studies; Plant-Based Agribusiness; Patents; Emerging Markets; Health Care and Treatment; Business and Stakeholder Relations; Cross-Cultural and Cross-Border Issues; Pharmaceutical Industry; Pharmaceutical Industry
Choudhury, Prithwiraj, and Tarun Khanna. "Bio-Piracy or Prospering Together? Fuzzy Set and Qualitative Analysis of Herbal Patenting by Firms." Harvard Business School Working Paper, No. 14-081, February 2014.
- September 1996
- Case
Food and Drug Administration: Business as Unusual at CDER
By: Steven C. Wheelwright and James Leonard
Wheelwright, Steven C., and James Leonard. "Food and Drug Administration: Business as Unusual at CDER." Harvard Business School Case 697-022, September 1996.
- November 1998
- Case
Wegmans Food Markets: Diabetes Counseling
By: Ray A. Goldberg, David E. Bell and Ann Leamon
Danny Wegman, president of Wegmans Food Markets, is trying to decide how to evaluate the success of a nutrition-counseling program for diabetics, and whether and how to expand the program beyond the two stores currently involved. Wegmans, with 57 stores and $2.3... View Details
Keywords: Performance Evaluation; Expansion; Programs; Human Needs; Financial Management; Health Care and Treatment; Nutrition; Consumer Behavior; Pharmaceutical Industry; Pharmaceutical Industry
Goldberg, Ray A., David E. Bell, and Ann Leamon. "Wegmans Food Markets: Diabetes Counseling." Harvard Business School Case 599-057, November 1998.
- 16 Jun 2015
- First Look
First Look: June 16, 2015
particularly in the vaccine space, had begun to attract the attention of much larger pharmaceutical companies. While there was much appeal to working with these companies, these relationships could also challenge Crucell's independence.... View Details
Keywords: Sean Silverthorne
- 18 Jun 2001
- Research & Ideas
When In-House Research Isn’t Enough
protection in the pharmaceutical and life sciences arena, said Chesbrough. But if you're in IT, forget about it. Can you sustain the pace of innovation necessary for success? The answers to the previous questions have an impact on this... View Details
Keywords: by Jim Aisner
- 23 Aug 2018
- News
Healthcare Alumni Keep Learning Through Virtual Programming
pharmaceutical CEO’s perspective on what’s next in Alzheimer’s research; and a panel discussion on the digital transformation of health care. “While many other organizations might claim to offer similar topics, the VRT series is designed... View Details
- 18 Nov 2014
- First Look
First Look: November 18
were the strengths and challenges facing this model? How would the model evolve in the future? And how would new, similar collaboration models surfacing at other major pharmaceutical companies pose a threat to the Pfizer model? Purchase... View Details
Keywords: Sean Silverthorne
- 21 Nov 2006
- First Look
First Look: November 21, 2006
cost to identify and investigate. The Effect of File Sharing on Record Sales: An Empirical Analysis Authors:Felix Oberholzer-Gee and Koleman Strumpf Periodical:Journal of Political Economy (forthcoming) Abstract For industries ranging from software to View Details
Keywords: Sean Silverthorne
- 12 Oct 2006
- First Look
First Look: October 12, 2006
pharmaceutical companies, government regulators—can play a role in righting the industry. The payoff? Valuable improvements in health care and a shinier future for human well-being. Pre-order this book:... View Details
Keywords: Sean Silverthorne
- 28 Aug 2017
- Research & Ideas
Should Industry Competitors Cooperate More to Solve World Problems?
to be innovative, really providing service to customers and attracting top talent. They are now becoming utilities, facing an incredible amount of regulation largely because of their own conduct failures. Third, they could reduce risk from exposure to major scandals.... View Details
- 12 Nov 2013
- First Look
First Look: November 12
GlaxoSmithKline: Sourcing Complex Professional Services Pharmaceutical company GlaxoSmithKline (GSK) uses an innovative new approach to procuring outside legal counsel: it replaces relationship-based selection and law firms' traditional... View Details
Keywords: Sean Silverthorne
- 25 Oct 2004
- Research & Ideas
Planning for Surprises
just two suppliers, while Great Britain has five suppliers to reduce the risk of supply disruptions. While fear of lawsuits has played a role, the fundamental problem is that the economics of vaccine production are unattractive for View Details
Keywords: by Martha Lagace